share_log

Are Robust Financials Driving The Recent Rally In WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock?

Are Robust Financials Driving The Recent Rally In WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock?

是穩健的金融股推動了藥明康德股份有限公司(上海證券交易所代碼:603259)最近的反彈嗎?
Simply Wall St ·  2023/01/08 19:30

WuXi AppTec's (SHSE:603259) stock is up by a considerable 22% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Specifically, we decided to study WuXi AppTec's ROE in this article.

藥明康德(上海證券交易所代碼:603259)的股票在過去三個月裏上漲了22%。鑑於該公司令人印象深刻的業績,我們決定更仔細地研究其財務指標,因為公司的長期財務健康狀況通常決定着市場結果。具體地説,我們決定在本文中研究藥明康德的淨資產收益率。

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

淨資產收益率,即股本回報率,是評估一家公司從股東那裏獲得投資回報的有效程度的有用工具。換句話説,這是一個衡量公司股東提供的資本回報率的盈利比率。

See our latest analysis for WuXi AppTec

參見我們對藥明康德的最新分析

How To Calculate Return On Equity?

如何計算股本回報率?

ROE can be calculated by using the formula:

可使用以下公式計算淨資產收益率:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率=(持續經營的)淨利潤?股東權益

So, based on the above formula, the ROE for WuXi AppTec is:

因此,根據上述公式,藥明康德的淨資產收益率為:

20% = CN¥9.0b ÷ CN¥45b (Based on the trailing twelve months to September 2022).

20%=CN元90億×CN元450億元(基於截至2022年9月的12個月)。

The 'return' is the amount earned after tax over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.20 in profit.

“報税表”是過去12個月的税後收入。這意味着,股東權益每增加1元,公司就會產生0.20元的利潤。

What Has ROE Got To Do With Earnings Growth?

淨資產收益率與盈利增長有什麼關係?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

我們已經證實,淨資產收益率是一家公司未來收益的有效盈利指標。根據公司將這些利潤再投資或“保留”多少,以及這樣做的效率如何,我們就能夠評估一家公司的收益增長潛力。一般來説,在其他條件相同的情況下,股本回報率和利潤留存較高的公司比不具備這些特徵的公司有更高的增長率。

WuXi AppTec's Earnings Growth And 20% ROE

藥明康德的盈利增長和20%的淨資產收益率

At first glance, WuXi AppTec seems to have a decent ROE. On comparing with the average industry ROE of 12% the company's ROE looks pretty remarkable. This probably laid the ground for WuXi AppTec's significant 36% net income growth seen over the past five years. We reckon that there could also be other factors at play here. Such as - high earnings retention or an efficient management in place.

乍一看,藥明康德似乎有不錯的淨資產收益率。與12%的行業平均淨資產收益率相比,該公司的淨資產收益率看起來相當驚人。這可能為藥明康德在過去五年中淨收入大幅增長36%奠定了基礎。我們認為,可能還有其他因素在起作用。例如-高收益留存或有效的管理到位。

As a next step, we compared WuXi AppTec's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 36% in the same period.

下一步,我們將藥明康德的淨收入增長與行業進行了比較,發現該公司與同期36%的行業平均增長率相比,有着類似的增長數字。

past-earnings-growth
SHSE:603259 Past Earnings Growth January 9th 2023
上證所:過去603259的收益增長2023年1月9日

Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for 603259? You can find out in our latest intrinsic value infographic research report.

盈利增長是股票估值的一個重要因素。對於投資者來説,重要的是知道市場是否已經消化了公司預期的收益增長(或下降)。這有助於他們確定這隻股票是為光明還是黯淡的未來做準備。市場是否已經消化了603259的未來前景?你可以在我們最新的內在價值信息圖研究報告中找到答案。

Is WuXi AppTec Efficiently Re-investing Its Profits?

藥明康德是否有效地將其利潤進行了再投資?

WuXi AppTec has a really low three-year median payout ratio of 22%, meaning that it has the remaining 78% left over to reinvest into its business. So it looks like WuXi AppTec is reinvesting profits heavily to grow its business, which shows in its earnings growth.

藥明康德的三年中值派息率非常低,只有22%,這意味着它還有剩餘的78%可以再投資於自己的業務。因此,藥明康德似乎在將利潤進行大量再投資,以實現業務增長,這從其盈利增長中可見一斑。

Moreover, WuXi AppTec is determined to keep sharing its profits with shareholders which we infer from its long history of three years of paying a dividend. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 21% of its profits over the next three years. Accordingly, forecasts suggest that WuXi AppTec's future ROE will be 19% which is again, similar to the current ROE.

此外,藥明康德決心繼續與股東分享利潤,這是我們從其派息三年的悠久歷史中推斷出來的。在研究了最新的分析師共識數據後,我們發現,預計該公司在未來三年將繼續支付約21%的利潤。因此,預測顯示,藥明康德未來的淨資產收益率將為19%,與目前的淨資產收益率相似。

Conclusion

結論

On the whole, we feel that WuXi AppTec's performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

總體來説,我們覺得藥明康德的表現是相當不錯的。特別是,我們喜歡該公司對其業務進行大量再投資,並以高回報率進行投資。不出所料,這導致了令人印象深刻的收益增長。話雖如此,最新的行業分析師預測顯示,該公司的收益增長預計將放緩。要了解更多有關該公司未來收益增長預測的信息,請查看以下內容免費報告分析師對該公司的預測,以瞭解更多信息。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論